NASDAQ · Financial Statements
NeuBase Therapeutics, Inc. (NBSE) Financial Statements
$0.38
NASDAQ: NBSE
Market Cap $1.42M
Overview Financials Dividend NeuBase Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-34.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2018 2019 2020 2021 2022 Revenue $0 $0 $0 $0 $0 Operating Profit $-14.0M $-26.0M $-17.0M $-27.0M $-33.0M Net Profit $-13.0M $-27.0M $-17.0M $-26.0M $-34.0M EPS $-93.57 $-65.49 $-17.60 $-18.80 $-21.08 Op Margin — — — — —
Balance Sheet (USD)
Metric 2018 2019 2020 2021 2022 Total Assets $12.0M $13.0M $34.0M $64.0M $33.0M Total Liabilities $1.0M $3.0M $3.0M $10.0M $10.0M Cash $4.0M $10.0M $32.0M $53.0M $23.0M Borrowings $0 $0 $0 $7.0M $6.0M
Cash Flow (USD)
Metric 2018 2019 2020 2021 2022 Operating Cash Flow $-9.0M $-3.0M $-11.0M $-19.0M $-29.0M Investing Cash Flow $1.0M $-1.0M $-2.0M $-4.0M $-1.0M Financing Cash Flow $0 $14.0M $33.0M $42.0M $0 Net Cash Flow $-9.0M $10.0M $22.0M $21.0M $-30.0M Free Cash Flow $-9.0M $-3.0M $-11.0M $-20.0M $-29.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA 0.48 FCF Yield -2079.10% Quick Ratio 5.95 Interest Coverage -1385.55 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock